Merck & Co., Inc. (MRK)
NYSE: MRK · IEX Real-Time Price · USD
128.97
+1.67 (1.31%)
At close: Jul 11, 2024, 4:00 PM
129.70
+0.73 (0.57%)
Pre-market: Jul 12, 2024, 7:30 AM EDT

Company Description

Merck & Co., Inc. operates as a healthcare company worldwide.

It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products.

The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians, wholesalers, government entities, veterinarians, distributors, animal producers, farmers, and pet owners.

It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications.

The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.

Merck & Co., Inc.
Merck & Co. logo
Country United States
Founded 2000
Industry Drug Manufacturers - General
Sector Healthcare
Employees 72,000
CEO Robert M. Davis J.D.

Contact Details

Address:
2000 Galloping Hill Road
Kenilworth, New Jersey 07033
United States
Phone 908-740-4000
Website merck.com

Stock Details

Ticker Symbol MRK
Exchange NYSE
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000310158
CUSIP Number 58933Y105
ISIN Number US58933Y1055
Employer ID 22-1918501
SIC Code 2834

Key Executives

Name Position
Robert M. Davis J.D. Chairman, President and Chief Executive Officer
Caroline Litchfield Executive Vice President and Chief Financial Officer
Jennifer L. Zachary Executive Vice President and General Counsel
Dr. Dean Y. Li M.D., Ph.D. Executive Vice President and President of Merck Research Laboratories
Chirfi Guindo Senior Vice President and Chief Marketing Officer of Human Health
Dalton E. Smart III Senior Vice President of Finance, Principal Accounting Officer and Global Controller
David Michael Williams Executive Vice President and Chief Information and Digital Officer
Peter Dannenbaum Vice President of Investor Relations
Lisa LeCointe-Cephas Senior Vice President and Chief Ethics and Compliance Officer
Cristal N. Downing Executive Vice President and Chief Communications and Public Affairs Officer

Latest SEC Filings

Date Type Title
Jun 25, 2024 11-K Annual report of employee stock purchase, savings and similar plans
Jun 25, 2024 11-K Annual report of employee stock purchase, savings and similar plans
Jun 25, 2024 11-K Annual report of employee stock purchase, savings and similar plans
May 30, 2024 CERT Certification by an exchange approving securities for listing
May 30, 2024 8-A12B Registration of securities
May 30, 2024 8-K Current Report
May 28, 2024 SD Form - SD
May 20, 2024 424B5 Filing
May 15, 2024 424B5 Filing
May 14, 2024 POSASR Filing